Loading...
Market
Story
BridgeBio Receives FDA Approval for Heart Disease Drug Attruby™ (acoramidis)
Nov 23, 2024, 12:12 AM
BridgeBio Pharma Inc. (BBIO) has received FDA approval for its drug Attruby™ (acoramidis), a near-complete TTR stabilizer (≥90%), to reduce cardiovascular death and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The approval will trigger a $500 million payment to BridgeBio under its royalty funding agreement. BridgeBio will provide further details on the Attruby label and access programs in a management call on November 22, 2024, at 8:00 pm ET. The approval is seen as a significant milestone for the company, and the share price is expected to react positively.
View original story
Similar markets
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%